Dawn M. Carlson

2.2k total citations · 1 hit paper
44 papers, 1.1k citations indexed

About

Dawn M. Carlson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dawn M. Carlson has authored 44 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Dawn M. Carlson's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lipoproteins and Cardiovascular Health (11 papers). Dawn M. Carlson is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lipoproteins and Cardiovascular Health (11 papers). Dawn M. Carlson collaborates with scholars based in United States, Singapore and Canada. Dawn M. Carlson's co-authors include Justin L. Ricker, Jiang Qian, Pei‐Jer Chen, Mark D. McKee, Călin Cainap, Hongming Pan, Ferry A.L.M. Eskens, Vera Gorbunova, Yoon‐Koo Kang and Wen‐Tsung Huang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Dawn M. Carlson

42 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

2014 465 citations Călin Cainap, Shukui Qin et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Dawn M. Carlson

Since Specialization

Citations

This map shows the geographic impact of Dawn M. Carlson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn M. Carlson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn M. Carlson more than expected).

Fields of papers citing papers by Dawn M. Carlson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn M. Carlson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn M. Carlson. The network helps show where Dawn M. Carlson may publish in the future.

Co-authorship network of co-authors of Dawn M. Carlson

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn M. Carlson. A scholar is included among the top collaborators of Dawn M. Carlson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn M. Carlson. Dawn M. Carlson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib 2015 ·Lung Cancer ·Evelyn McKeegan, Peter Ansell, Gerard J. Davis, (unknown), (unknown), Susan H. Gawel, Barry L. Dowell, Anahita Bhathena, Arunava Chakravartty, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, Suresh S. Ramalingam, Viswanath Devanarayan	13
2	Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer 2014 ·Clinical Colorectal Cancer ·Bert H. O’Neil, Călin Cainap, Eric Van Cutsem, (unknown), Christos S. Karapetis, Jordan Berlin, Richard M. Goldberg, Qin Qin, Jiang Qian, Justin L. Ricker, (unknown), Mark D. McKee, Dawn M. Carlson, Tae Won Kim	17
3	Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial breakdown → 2014 ·Journal of Clinical Oncology ·Călin Cainap, Shukui Qin, Wen‐Tsung Huang, Ik Joo Chung, Hongming Pan, Ying Cheng, Masatoshi Kudo, Yoon‐Koo Kang, Pei‐Jer Chen, (unknown), Vera Gorbunova, Ferry A.L.M. Eskens, Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, (unknown)	465
4	A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC) 2014 ·Cancer Chemotherapy and Pharmacology ·Hidehito Horinouchi, Noboru Yamamoto, Hiroshi Nokihara, Takeshi Horai, Makoto Nishio, Fumiyoshi Ohyanagi, Atsushi Horiike, Kazuhiko Nakagawa, Masaaki Terashima, Takafumi Okabe, Hiroyasu Kaneda, Mark D. McKee, Dawn M. Carlson, Hao Xiong, Tomohide Tamura	12
5	Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients 2013 ·Clinical Pharmacokinetics ·Ahmed Hamed Salem, (unknown), Dawn M. Carlson	10
6	A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease 2013 ·Clinical Therapeutics ·D. Weinstein, Laura Williams, Dawn M. Carlson, Maureen T. Kelly, (unknown), Carolyn M. Setze, (unknown), James C. Stolzenbach	8
7	Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma 2013 ·Clinical Therapeutics ·Yi‐Lin Chiu, Dawn M. Carlson, Rajendra Pradhan, Justin L. Ricker	11
8	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia 2012 ·Leukemia & lymphoma ·Eunice S. Wang, Karen Yee, Liang Piu Koh, Donna E. Hogge, Sari H. Enschede, Dawn M. Carlson, Matthew W. Dudley, Keith B. Glaser, Evelyn McKeegan, Daniel H. Albert, Xiaohui Li, Rajendra Pradhan, Wendy Stock	18
9	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial 2012 ·Cardiovascular Drugs and Therapy ·Michael H. Davidson, Robert S. Rosenson, Kevin C. Maki, Stephen J. Nicholls, Christie M. Ballantyne, Carolyn M. Setze, Dawn M. Carlson, James C. Stolzenbach	12
10	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure 2011 ·European Journal of Cancer ·Nizar M. Tannir, (unknown), Christian Kollmannsberger, Marc S. Ernstoff, David J. Perry, Leonard J. Appleman, Edwin M. Posadas, Daniel Cho, Toni K. Choueiri, A. Coates, Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Jihong Chen, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, M. Dror Michaelson	24
11	Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer 2011 ·Journal of Thoracic Oncology ·(unknown), Glenwood Goss, Ravi Salgia, Benjamin Besse, David R. Gandara, Nasser H. Hanna, James Chih‐Hsin Yang, Raymond Thertulien, M. S. Wertheim, Julien Mazières, (unknown), (unknown), Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Qin Qin, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, Ross A. Soo	54
12	Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. 2011 ·Journal of Clinical Oncology ·Edwin M. Posadas, Nizar M. Tannir, (unknown), Marc S. Ernstoff, Christian Kollmannsberger, Jane Qian, Peter Ansell, Evelyn McKeegan, Mac McKee, Justin L. Ricker, Dawn M. Carlson, M. Dror Michaelson	3
13	Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study 2010 ·Cardiovascular Drugs and Therapy ·Eli M. Roth, Robert S. Rosenson, Dawn M. Carlson, (unknown), Carolyn M. Setze, James W. Blasetto, Nardev S. Khurmi, James C. Stolzenbach, Laura Williams	20
14	Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies 2010 ·Clinical Cardiology ·Carl J. Pepine, Terry A. Jacobson, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, James C. Stolzenbach, Laura Williams	7
15	Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus 2010 ·Cardiovascular Drugs and Therapy ·Robert S. Rosenson, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Boaz Hirshberg, James C. Stolzenbach, Laura Williams	15
16	Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia 2010 ·American Journal of Cardiovascular Drugs ·Eli M. Roth, James M. McKenney, Maureen T. Kelly, Carolyn M. Setze, Dawn M. Carlson, Alex Gold, James C. Stolzenbach, Laura Williams, Peter H. Jones	31
17	Efficacy and Safety of Fenofibric Acid and Rosuvastatin Combination Therapy in Women 55 Years or Older (Post-Menopausal) with Mixed Dyslipidemia 2009 ·Journal of clinical lipidology ·Anne C. Goldberg, Nanette K. Wenger, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, Michael D. Cressman, James C. Stolzenbach	1
18	Characterization of human circulating endothelial cells to monitor response to antitumor therapy in human clinical trials 2006 ·Clinical Cancer Research ·Evelyn McKeegan, Dawn M. Carlson, Raymond A. Knight, Milagros Colon-Lopez, Peter J. DeVries, Rod Humerickhouse, Rick Lesniewski	1
19	A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS) 2005 ·Journal of Clinical Oncology ·Laurence H. Baker, G. D. Demetri, David S. Mendelson, Eric K. Rowinsky, Evelyn McKeegan, Raymond A. Knight, Dawn M. Carlson, Michael Lobell	14
20	Lithium toxicity: two case reports. 2002 ·PubMed ·(unknown), Dawn M. Carlson, John F. Madden	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact